Thorsten Lewalter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4338101/publications.pdf

Version: 2024-02-01

471509 254184 1,934 50 17 43 citations h-index g-index papers 60 60 60 2624 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet, The, 2019, 394, 1335-1343.	13.7	465
2	Impact of Complete Versus Incomplete Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003337.	4.8	213
3	Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal. 2019. 40. 3757-3767.	2.2	211
4	The Atrial Fibrillation Ablation Pilot Study: an European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. European Heart Journal, 2014, 35, 1466-1478.	2.2	180
5	Cerebral Diffusion-Weighted Magnetic Resonance Imaging: A Tool to Monitor the Thrombogenicity of Left Atrial Catheter Ablation. Journal of Cardiovascular Electrophysiology, 2005, 17, 050914081521014.	1.7	135
6	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace, 2017, 19, euw141.	1.7	120
7	Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. American Heart Journal, 2018, 196, 105-112.	2.7	80
8	Acute and Long-Term Effects of Consecutive Radiofrequency Applications on Conduction Properties of the Subeustachian Isthmus in Type I Atrial Flutter. Journal of Cardiovascular Electrophysiology, 1998, 9, 152-163.	1.7	79
9	New Insights Into the Initiation of Atrial Fibrillation. Circulation, 2006, 113, 1933-1941.	1.6	61
10	Verification of Linear Lesions Using a Noncontact Multielectrode Array Catheter versus Conventional Contact Mapping Techniques. Journal of Cardiovascular Electrophysiology, 1999, 10, 791-798.	1.7	37
11	Individualized Selection of Pacing Algorithms for the Prevention of Recurrent Atrial Fibrillation: Results from the VIP Registry. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 124-134.	1.2	37
12	Gold-Tip Electrodes-A New "Deep Lesion" Technology for Catheter Ablation? In Vitro Comparison of a Gold Alloy Versus Platinum-Iridium Tip Electrode Ablation Catheter. Journal of Cardiovascular Electrophysiology, 2005, 16, 770-772.	1.7	35
13	Gold vs. platinum-iridium tip catheter for cavotricuspid isthmus ablation: the AURUM 8 study. Europace, 2011, 13, 102-108.	1.7	25
14	Implant-based multi-parameter telemonitoring of patients with heart failure and a defibrillator with vs. without cardiac resynchronization therapy option: a subanalysis of the IN-TIME trial. Clinical Research in Cardiology, 2019, 108, 1117-1127.	3.3	23
15	In vitro comparison of platinum-iridium and gold tip electrodes: lesion depth in 4 mm, 8 mm, and irrigated-tip radiofrequency ablation catheters. Europace, 2009, 11, 565-570.	1.7	21
16	Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. European Heart Journal, 2020, 41, 4497-4504.	2.2	20
17	Interventional occlusion of left atrial appendage in patients with atrial fibrillation. Acute and long-term outcome of occluder implantation in the LAARGE Registry. Journal of Interventional Cardiac Electrophysiology, 2020, 58, 273-280.	1.3	19
18	Predictors of success in radiofrequency catheter ablation of atrial flutter. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 121-125.	1.3	14

#	Article	IF	CITATIONS
19	"Largest Amplitude Ablation―is the Optimal Approach for Typical Atrial Flutter Ablation: A Subanalysis from the AURUM 8 Study. Journal of Cardiovascular Electrophysiology, 2012, 23, 479-485.	1.7	14
20	Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis. Clinical Research in Cardiology, 2021, 110, 831-840.	3.3	14
21	Radiofrequency Catheter Ablation of an Incessant Ventricular Tachycardia Following Valve Surgery. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 105-108.	1.2	13
22	Heart rate during exercise: What is the optimal goal of rate adaptive pacemaker therapy?. American Heart Journal, 1994, 127, 1026-1030.	2.7	12
23	Comparison in Patients < 75 Years of Age - Versus – Those > 75 Years on One-year-Events With Atrial Fibrillation and Left Atrial Appendage Occluder (From the Prospective Multicenter German) Tj ETQq1 1 0.7	'84 3. 1⁄4 rgl	BT / © verlock
24	Identification of "substrate fibrillators―and "trigger fibrillators―by pacemaker diagnostics. Heart Rhythm, 2006, 3, 682-688.	0.7	9
25	Morphologyâ€Enhanced Atrial Event Classification Improves Sensing in Pacemakers. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1455-1463.	1.2	8
26	Heart rate to work rate relation throughout peak exercise in normal subjects as a guideline for rate-adaptive pacemaker programming. American Journal of Cardiology, 1995, 76, 812-816.	1.6	7
27	Monitoring in the management of atrial fibrillation. Europace, 2012, 14, 591-592.	1.7	5
28	"First-degree AV blockâ€"a benign entity?―Insertable cardiac monitor in patients with 1st-degree AV block reveals presence or progression to higher grade block or bradycardia requiring pacemaker implant. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 303-306.	1.3	5
29	Relevance of Monitoring Atrial Fibrillation in Clinical Practice. Arrhythmia and Electrophysiology Review, 2012, 1, 54.	2.4	5
30	Accessory Pathway Catheter Ablation Inside the Neck of a Coronary Sinus Diverticulum. Journal of Cardiovascular Electrophysiology, 2003, 14, 1386-1386.	1.7	4
31	Efficacy and complications of cavo-tricuspid isthmus-dependent atrial flutter ablation in patients with and without structural heart disease: results from the German Ablation Registry. Journal of Interventional Cardiac Electrophysiology, 2021, 61, 55-62.	1.3	4
32	Impact of atrial fibrillation pattern on outcomes after left atrial appendage closure: lessons from the prospective LAARGE registry. Clinical Research in Cardiology, 2022, 111, 511-521.	3.3	4
33	Interventional occlusion of left atrial appendage in patients with atrial fibrillation. Genderâ€related outcomes in the German LAARGE Registry. Journal of Cardiovascular Electrophysiology, 2021, 32, 2636-2644.	1.7	4
34	Circumferential pulmonary vein mapping and ablation in focal atrial fibrillation: single catheter technique. Journal of Interventional Cardiac Electrophysiology, 2002, 7, 165-170.	1.3	3
35	Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2010, 55, 1051-1052.	2.8	3
36	An optimized approach for right atrial flutter ablation: a post hoc analysis of the AURUM 8 study. Journal of Interventional Cardiac Electrophysiology, 2017, 48, 159-166.	1.3	2

#	Article	IF	CITATIONS
37	Anticoagulation versus antiplatelet therapy after percutaneous left atrial appendage closure—subanalysis from the multicenter LAARGE registry. Journal of Interventional Cardiac Electrophysiology, 2022, 64, 489-496.	1.3	2
38	New missense mutation (G626V) in the predicted selectivity filter of the HERG channel associated with familial long QT syndrome. Human Mutation, 2000, 15, 584-584.	2.5	1
39	Decremental pulmonary venous pulse propagation: impact for catheter ablation in focal atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2003, 9, 269-273.	1.3	1
40	Differences in Clinical and Echocardiographic Parameters between Paroxysmal and Persistent Atrial Flutter in the AURUM 8 Study: Targets for Prevention of Persistent Arrhythmia?. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 194-202.	1.2	1
41	REduction of THRomboembolic EVents during Ablation using the laserballoon: The RETHREVA registry. Journal of Cardiovascular Electrophysiology, 2018, 29, 365-374.	1.7	1
42	Chronotropic Incompetence. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 361-364.	1.0	0
43	Antiarrhythmische Hybridtherapie. Herzschrittmachertherapie Und Elektrophysiologie, 2003, 14, 1-2.	0.8	O
44	Katheterablation von Antiarrhythmika-induziertem Vorhofflattern bei Patienten mit rekurrierendem Vorhofflimmern. Herzschrittmachertherapie Und Elektrophysiologie, 2003, 14, 8-14.	0.8	0
45	Interventional Electrophysiology: New frontiers for an ever expanding discipline. Journal of Interventional Cardiac Electrophysiology, 2008, 22, 85-86.	1.3	O
46	Innovations in drug treatment of atrial fibrillation. Clinical Research in Cardiology Supplements, 2010, 5, 47-50.	2.0	0
47	Stimulating a natural process for PFO closure. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 7-8.	1.3	0
48	Successful catheter ablation of a left atrial appendage occluder-related atypical atrial flutter. Journal of Interventional Cardiac Electrophysiology, 2021, 62, 215-216.	1.3	0
49	Influence of severe anemia on procedural safety and one-year outcome after left atrial appendage closure: Insights from a very high-risk cohort. IJC Heart and Vasculature, 2022, 38, 100946.	1.1	0
50	Adverse events and stroke prevention by interventional left atrial appendage occlusion in patients with low CHA ⟨sub⟩2⟨ sub⟩ DS ⟨sub⟩2⟨ sub⟩ â€VASc scoreâ€"results from the multicenter German LAARGE registry. Catheterization and Cardiovascular Interventions, 2022, , .	1.7	0